The effect of intraperitoneal administration of BromAc on blood parameters: phase 1 study.

Ke, Kevin; Pillai, Krishna; Mekkawy, Ahmed H; Akhter, Javed; Badar, Samina; Valle, Sarah J; Morris, David L

Ke, Kevin; Pillai, Krishna; Mekkawy, Ahmed H; Akhter, Javed; Badar, Samina; Valle, Sarah J; Morris, David L.

Afiliación

Ke K; Department of Surgery, St. George Hospital, Kogarah, NSW, 2217, Australia.
Pillai K; Mucpharm Pty Ltd, Kogarah, NSW, 2217, Australia.
Mekkawy AH; Department of Surgery, St. George Hospital, Kogarah, NSW, 2217, Australia.
Akhter J; Mucpharm Pty Ltd, Kogarah, NSW, 2217, Australia.
Badar S; Department of Surgery, St. George Hospital, Kogarah, NSW, 2217, Australia.
Valle SJ; Mucpharm Pty Ltd, Kogarah, NSW, 2217, Australia.
Morris DL; Department of Surgery, St. George Hospital, Kogarah, NSW, 2217, Australia.

Discov Oncol ; 12(1): 25, 2021 Aug 16.

Article en En | MEDLINE | ID: mdl-35201475

Palabras clave

Acetylcysteine; Blood; BromAc®; Bromelain; PMP; Pseudomyxoma peritonei

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Discov Oncol Año: 2021 Tipo del documento: Article País de afiliación: Australia